Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in relapsed/refractory extranodal NK/T-cell lymphoma (nasal type)
CTR20170818Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Innovent Biologics. Started Aug 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on CTR20170818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170818.